Delaware 150th General Assembly (2019-2020) Status: Enacted Bipartisan · 14 D · 1 R cosponsors

HB 263 — AN ACT TO AMEND TITLE 18 AND TITLE 29 OF THE DELAWARE CODE RELATING TO COST SHARING IN PRESCRIPTION INSULIN DRUGS.

Last action — Signed by Governor

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. ✓
    Passed House
  4. ✓
    Passed Senate
  5. ✓
    To Executive
  6. 6
    Enacted

This bill has been enacted into law. Introduced January 09, 2020. Enacted.

Odds of enactment

High chance

Based on the sponsor, cosponsors, and committee posture, this bill has a high chance of becoming law.

Upgrade to see the exact probability and what's driving it.

A statistical estimate from our own model of past outcomes — an insight, not a guarantee. Policymaking is volatile.

Prognosis

Likely to advance 98% · high confidence
  • Enacted

    Current position in the legislative process.

  • 31 sponsors

    6 primary, 25 co-sponsors signed on.

  • Bipartisan support

    Sponsored across 2 parties (14 D · 1 R) — cross-party backing.

  • Cleared a recorded vote

    Passed 2 recorded votes so far.

Based on stage, sponsorship breadth, committee status, recorded votes, and cross-state momentum — a description of the observable signals, not a prediction.

Summary

This Act requires that individual, group, and State employee insurance plans cap the amount an individual must pay for insulin prescriptions at $100 a month and must include at least 1 formulation of insulin on the lowest tier of the drug formulary developed and maintained by the carrier.

Bill Text

What changed in the latest version

62 added · 54 removed

62 line(s) added, 54 removed.

→
Previous
Latest
Minor-Brown HOUSE OF REPRESENTATIVES 150th GENERAL ASSEMBLY HOUSE AMENDMENT NO.
Dorsey Walker & Rep.
1 TO HOUSE BILL NO.
Minor-Brown & Sen.
263 AMEND House Bill No.
Townsend & Sen.
263 on lines 10, 27, and 43 by inserting the following after “prescriptions.”:
Brown Reps.
“The $100 per month cap includes deductible payments and cost-sharing amounts charged once a deductible is met.”.
Baumbach, Bolden, Brady, Chukwuocha, Cooke, Griffith, Heffernan, Jaques, K.
FURTHER AMEND House Bill No.
Johnson, Kowalko, Longhurst, Lynn, Mitchell, Osienski, Seigfried, Michael Smith, Viola, K.
263 on lines 11, 28, and 44, by deleting “insulin” between “of” and “on” and inserting in lieu thereof “each of the following types of prescription insulin drugs”.
Williams;
FURTHER AMEND House Bill No.
Sens.
263 on lines 12 and 29 by deleting “carrier.” after “the” and inserting in lieu thereof the following:
Lockman, Lopez, McDowell, Paradee, Sokola, Sturgeon, Walsh HOUSE OF REPRESENTATIVES 150th GENERAL ASSEMBLY HOUSE BILL NO.
“carrier:
263 AN ACT TO AMEND TITLE 18 AND TITLE 29 OF THE DELAWARE CODE RELATING TO COST SHARING IN PRESCRIPTION INSULIN DRUGS.
a.
BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF DELAWARE:
Rapid-acting.
Section 1.
b.
Amend Chapter 33, Title 18 of the Delaware Code by making deletions as shown by strike through and insertions as shown by underline as follows:
Short-acting.
§ 3344B.
b.
Cost sharing in prescription insulin drugs.
Intermediate-acting.
(a) For purposes of this section, “prescription insulin drug” means a drug containing insulin that is dispensed under Chapter 47 of Title 16 for the treatment of diabetes.
c.
(b) An individual health insurance policy, contract, or certificate that is delivered, issued for delivery, renewed, extended, or modified in this State that provides coverage for prescription insulin drugs must do all of the following:
Long-acting.
(1) Cap the total amount that a covered individual is required to pay for covered prescription insulin drugs at no more than $100 per month for each enrolled individual, regardless of the amount or types of insulin needed to fill the covered individual’s prescriptions.
(3) For purposes of paragraph (b)(2) of this section, the “lowest tier of the drug formulary” means either of the following:
(2) Include at least 1 formulation of insulin on the lowest tier of the drug formulary developed and maintained by the carrier.
a.
(c) Nothing in this section prevents the operation of a policy provision required by this section as a deductible, coinsurance, allowable charge limitation, coordination of benefits, or a provision restricting coverage to services by a licensed, certified, or carrier-approved provider or facility.
If the prescription insulin drug is a generic drug, the lowest tier for generic drugs.
(d) This section applies to all policies, contracts, or certificates issued, renewed, modified, altered, amended, or reissued after January 1, 2021.
b.
Section 2.
If the prescription insulin drug is a brand-name drug, the lowest tier for brand-name drugs.”.
Amend Chapter 35, Title 18 of the Delaware Code by making deletions as shown by strike through and insertions as shown by underline as follows:
FURTHER AMEND House Bill No.
§ 3560A.
263 on lines 13 and 30 by deleting “Nothing” between “(c)” and “in” and inserting in lieu thereof the following:
Cost sharing in prescription insulin drugs.
“Except as provided under paragraph (b)(1) of this section, nothing”.
FURTHER AMEND House Bill No.
263 on line 17 and 34 by deleting “January 1, 2021.” after “after” and inserting in lieu thereof “December 31, 2020.”.
FURTHER AMEND House Bill No.
263 on line 23 by deleting “An individual” between “(b)” and “health” and inserting in lieu thereof “A group or blanket”.
01/29/2020 08:58 AM FURTHER AMEND House Bill No.
01/09/2020 08:13 AM (a) For purposes of this section, “prescription insulin drug” means a drug containing insulin that is dispensed under Chapter 47 of Title 16 for the treatment of diabetes.
263 on line 45 by deleting “carrier.” after “the” and inserting in lieu thereof the following:
(b) An individual health insurance policy, contract, or certificate that is delivered, issued for delivery, renewed, extended, or modified in this State that provides coverage for prescription insulin drugs must do all of the following:
“carrier:
(1) Cap the total amount that a covered individual is required to pay for covered prescription insulin drugs at no more than $100 per month for each enrolled individual, regardless of the amount or types of insulin needed to fill the covered individual’s prescriptions.
a.
(2) Include at least 1 formulation of insulin on the lowest tier of the drug formulary developed and maintained by the carrier.
Rapid-acting.
(c) Nothing in this section prevents the operation of a policy provision required by this section as a deductible, coinsurance, allowable charge limitation, coordination of benefits, or a provision restricting coverage to services by a licensed, certified, or carrier-approved provider or facility.
b.
(d) This section applies to all policies, contracts, or certificates issued, renewed, modified, altered, amended, or reissued after January 1, 2021.
Short-acting.
Section 3.
b.
Amend Chapter 52, Title 29 of the Delaware Code by making deletions as shown by strike through and insertions as shown by underline as follows:
Intermediate-acting.
§ 5212.
c.
Cost sharing in prescription insulin drugs.
Show all 62 changed rows (22 more)
Previous
Latest
Long-acting.
(a) For purposes of this section, “prescription insulin drug” means a drug containing insulin that is dispensed under Chapter 47 of Title 16 for the treatment of diabetes.
(3) For purposes of paragraph (b)(2) of this section, the “lowest tier of the drug formulary” means either of the following:
(b) The plan must provide coverage for prescription insulin drugs that does all of the following:
a.
(1) Caps the total amount that a covered individual is required to pay for covered prescription insulin drugs at no more than $100 per month for each enrolled individual, regardless of the amount or types of insulin needed to fill the covered individual’s prescriptions.
If the prescription insulin drug is a generic drug, the lowest tier for generic drugs.
(2) Includes at least 1 formulation of insulin on the lowest tier of the drug formulary developed and maintained by the carrier.
b.
SYNOPSIS This Act requires that individual, group, and State employee insurance plans cap the amount an individual must pay for insulin prescriptions at $100 a month and must include at least 1 formulation of insulin on the lowest tier of the drug formulary developed and maintained by the carrier.
If the prescription insulin drug is a brand-name drug, the lowest tier for brand-name drugs.
(c) The cap on the amount a covered individual is required to pay under paragraph (b)(1) of this section applies to an enrolled individual who is in compliance with all coordination of benefits policies of the plan, including spousal coordination of benefits.”.
SYNOPSIS This Amendment revises House Bill No.
263 by doing all of the following:
1.
Requires at least 1 formulation of each type of prescription insulin be on the lowest tier of the drug formulary.
2.
Defines the "lowest tier of the drug formulary" as the lowest tier for generic drugs, if the insulin is a generic and the lowest tier for brand-name drugs, if the insulin is brand-name.
3.
Clarifies that the $100 per month cost-sharing cap includes deductible payments and cost-sharing amounts charged once a deductible is met.
4.
Corrects the date for the applicability of this Act so it includes insurance plans that begin on January 1, 2021.
5.
Clarifies that the cap on the copay applies to covered individuals who are in compliance with the coordination of benefits policies under the State employee insurance plans.
6.
Corrects a typographical error.
01/29/2020 08:58 AM 5971500262
01/09/2020 08:13 AM 5971500224
View plain text versions (2)

Action History

  1. Signed by Governor

  2. Suspension of Rules in Senate

  3. Passed By Senate. Votes: 21 YES

  4. Assigned to Health & Social Services Committee in Senate

  5. Passed By House. Votes: 40 YES 1 ABSENT

  6. Amendment HA 2 to HB 263 - Stricken in House

  7. Amendment HA 1 to HB 263 - Passed In House by Voice Vote

  8. Amendment HA 2 to HB 263 - Introduced and Placed With Bill

  9. Amendment HA 1 to HB 263 - Introduced and Placed With Bill

  10. Reported Out of Committee (Health & Human Development) in House with 5 Favorable, 4 On Its Merits

  11. Introduced and Assigned to Health & Human Development Committee in House

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

6 sponsors · 25 co-sponsors · 31 not signed on

Not signed on (31)

31 members have not signed on to this bill.

Show all 31 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Votes

SM

Passed 21 Yea · 0 Nay
Party YeaNayPresentNot Voting
Unaffiliated 7000
Democratic 9000
Republican 5000
Total 21000
% of votes cast 100%0%0%0%
How each member voted (21)
Member Party Vote
Anthony Delcollo — Yea
Bruce C. Ennis — Yea
Catherine Cloutier — Yea
Colin Bonini — Yea
David B. McBride — Yea
Ernesto B Lopez — Yea
Harris B. McDowell — Yea
Bryan Townsend Democratic Yea
Darius J. Brown Democratic Yea
David P. Sokola Democratic Yea
John "Jack" Walsh Democratic Yea
Laura V. Sturgeon Democratic Yea
Nicole Poore Democratic Yea
S. Elizabeth Lockman Democratic Yea
Stephanie L. Hansen Democratic Yea
Trey Paradee Democratic Yea
Brian Pettyjohn Republican Yea
Bryant L. Richardson Republican Yea
Dave G. Lawson Republican Yea
David L. Wilson Republican Yea
Gerald W. Hocker Republican Yea

Official roll call →

SM

Passed 40 Yea · 0 Nay · 1 Other
Party YeaNayPresentNot Voting
Unaffiliated 16001
Democratic 12000
Republican 12000
Total 40001
% of votes cast 98%0%0%2%
How each member voted (41)
Member Party Vote
Andria L. Bennett — Yea
David Bentz — Yea
Earl G. Jaques Jr. — Yea
Gerald L. Brady — Yea
John A. Kowalko — Not Voting
John J. Viola — Yea
John L. Mitchell — Yea
Michael Ramone — Yea
Paul S. Baumbach — Yea
Peter C. Schwartzkopf — Yea
Quinton Johnson — Yea
Raymond Seigfried — Yea
Ruth Briggs King — Yea
Sean Matthews — Yea
Sherry Dorsey Walker — Yea
Stephen Smyk — Yea
Valerie Longhurst — Yea
Debra Heffernan Democratic Yea
Edward S. Osienski Democratic Yea
Franklin D. Cooke Democratic Yea
Kendra Johnson Democratic Yea
Kimberly Williams Democratic Yea
Krista Griffith Democratic Yea
Melissa Minor-Brown Democratic Yea
Nnamdi O. Chukwuocha Democratic Yea
Sean M. Lynn Democratic Yea
Stephanie T. Bolden Democratic Yea
William Bush Democratic Yea
William J. Carson Democratic Yea
Bryan W. Shupe Republican Yea
Charles S Postles Jr. Republican Yea
Daniel B. Short Republican Yea
Jeffrey N. Spiegelman Republican Yea
Jesse R. Vanderwende Republican Yea
Kevin S Hensley Republican Yea
Lyndon D. Yearick Republican Yea
Michael F. Smith Republican Yea
Richard G. Collins Republican Yea
Ronald E. Gray Republican Yea
Shannon Morris Republican Yea
Timothy D. Dukes Republican Yea

Official roll call →

Subjects

Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HB 263 do?
This Act requires that individual, group, and State employee insurance plans cap the amount an individual must pay for insulin prescriptions at $100 a month and must include at least 1 formulation of insulin on the lowest tier of the drug formulary developed and maintained by the carrier.
Who sponsors HB 263?
HB 263 is sponsored by Kimberly Williams (Democratic), Michael F. Smith (Republican), Edward S. Osienski (Democratic), Sean M. Lynn (Democratic), Kendra Johnson (Democratic), Debra Heffernan (Democratic), Krista Griffith (Democratic), Franklin D. Cooke (Democratic), Nnamdi O. Chukwuocha (Democratic), Stephanie T. Bolden (Democratic), John "Jack" Walsh, Laura V. Sturgeon, David P. Sokola (Democratic), Trey Paradee, S. Elizabeth Lockman (Democratic), Melissa Minor-Brown (Democratic), Darius J. Brown (Democratic), Bryan Townsend (Democratic), Gerald L. Brady, Earl G. Jaques Jr., John A. Kowalko, Valerie Longhurst, David Bentz, Andria L. Bennett, Sherry Dorsey Walker, Ernesto B Lopez, Harris B. McDowell, Paul S. Baumbach, John L. Mitchell, Raymond Seigfried, and John J. Viola.
What is the current status of HB 263?
This bill has been enacted into law. Introduced January 09, 2020. Enacted.
Where can I track HB 263?
Track HB 263 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HB 263

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Stay ahead of HB 263

Last checked for changes 2 months ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →